Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 24;13:1035616. doi: 10.3389/fimmu.2022.1035616

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Dai, Zhao, Hua, Cui, Zhang, Kang, Qu, Li, Li, Shen, Wang and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Expression of immune checkpoint molecules in EC. (A) PD-L1 expression in different EC molecular subtypes. The p value of Fisher’s exact test for overall comparison is given. (B, C) PD-L1⁺ CD68⁺ cell fractions in tumor parenchyma and mesenchyme. (D, E) CD8⁺ PD-1⁺ cell fractions in tumor parenchyma and mesenchyme. (F, G) The ratio of CD8⁺ PD-1⁺ cell fractions to CD8⁺ T cell fractions in tumor parenchyma and mesenchyme. For (B-G), the p values of Kruskal-Wallis test for overall comparisons are given, and significant levels in pairwise comparisons are shown in the figure. In all panels, n = 9 for TMB-H, 10 for NSMP, 11 for TP53 mutant. The dots above the boxplots indicate outliers. TMB-H, high tumor mutation burden; NSMP, no specific molecular profile; EC, endometrial cancer. *p < 0.05, **p < 0.01.